Anti-inflammatory profile of paricalcitol in hemodialysis patients: A prospective, open-label, pilot study

Journal of Clinical Pharmacology

Volumn 53, Issue 4, 2013, Pages 421-426

  Navarro González, Juan F ^a,b   Donate Correa, Javier ^a,b   Méndez, María L ^a   De Fuentes, Mercedes Muros ^a,b   García Pérez, Javier ^a   Mora Fernández, Carmen ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b GEENDIAB Grupo Español para el Estudio de la Nefropatía Diabética REDINREN RD12 0021 0019   (Spain)

Author keywords

Gene expression; Hemodialysis; Inflammation; Paricalcitol; Peripheral blood mononuclear cells

Indexed keywords

BETA ACTIN; C REACTIVE PROTEIN; CALCITRIOL; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; MESSENGER RNA; PARICALCITOL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; GENE EXPRESSION PROFILING; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; MALE; OPEN STUDY; PARATHYROID HORMONE BLOOD LEVEL; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REVIEW; SECONDARY HYPERPARATHYROIDISM; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS; CYTOKINES; ERGOCALCIFEROLS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PILOT PROJECTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RNA, MESSENGER;

EID: 84877845440     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.19     Document Type: Review

References (32)

1. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis. Kidney Int. 1999;55:648-658.
2. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton). 2006;11:36-41.
3. Jofré R, Rodríguez-Benítez P, López- Gómez JM, Pérez-García R. Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol. 2006;17:S274-S280.
4. Tetta C, David S, Mariano F, De Nitti C, Panichi V. Alterations of the cytokine network in hemodialysis. J Nephrol. 2001;14:S22-S29.
5. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-a. Central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 2005;67:1216-1233.
6. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63:1483-1490.
7. Fryer RM, Rakestraw PA, Nekane M, et al. Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephrol Physiol. 2007;106:76-81.
8. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 2007;72:709-715.
9. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D Receptor-mediated sequestration of NF-kB signaling. J Am Soc Nephrol. 2008;19:1741-1752.
10. Tan X, He W, Liu Y. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int. 2009;76:1248-1257.
11. He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/(-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol. 2011;22:90-103.
12. Guerrero F, Montes de Oca A, Aguilera-Tejero E, Zafra R, Rodríguez M, López I. The effect of vitamin D derivates on vascular calcification associated to inflammation. Nephrol Dial Transplant. 2012;27:2206-2212.
13. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008;52:249-255.
14. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol. N Engl J Med. 2003;349:446-456.
15. Andress DL. VitaminDin chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006;69:33-43.
16. Swaminathan S, Shah SV. Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease. Kidney Int. 2011;80: 453-463.
17. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-581.
18. Boström K. Proinflammatory vascular calcification. Cir Res. 2005;96:1219-1220.
19. Al-Aly Z. Arterial calcification: a tumor necrosis factor-alpha mediated vascular Wnt-opathy. Transl Res. 2008;151:233-239.
20. Shlipak MG, Fried LF, Crump E, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87-92.
21. Zocalli C, Tripepi G, Mallamachi F. Dissecting Inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J AmSoc Nephrol. 2006;17:S169-S173.
22. Barreto DV, Barreto FC, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and predialysis patients with chronic kidney disease. Kidney Int. 2012;77:550-556.
23. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2011;286:2107-2113.
24. Valdivielso JM, Ayus JC. Role of vitamin D receptor activators on cardiovascular risk. Kidney Int. 2008;74:S44-S49.
25. Cunningham J, Zehnder D. New vitamin D analogs and changing therapeutic paradigms. Kidney Int. 2011;79:702-707.
26. Moe SM, Zekonis M, Harezlak J, et al. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis. 2001;38:792-802.
27. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol. 2010;21:353-361.
28. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009;27:165-197.
29. Nathan C. Points to control in inflammation. Nature. 2002;420:846-852.
30. Kostulas N, Pelidou S, Kivisäkk P, Kostulas V, Link H. Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke. 1999;30:2174-2179.
31. Akatsu T, Nakamura M, Satoh M, Hiramori K. Increased mRNA expression of tumour necrosis factor-alpha and its converting enzyme in circulating leucocytes of patients with acute myocardial infarction. Clin Sci. 2003;105:39-44.
32. Ramirez R, Carracedo J, Berdud I, et al. Microinflammation in hemodialysis is related to a preactivated subset of monocytes. Hemodial Int. 2006;10:S24-S27.